

JUN. 29. 2004 3:51PM


OBLON SPIVAK

RECEIVED
CENTRAL FAX CENTER

NO. 365 P. 1

JUN 29 2004

OFFICIAL



ATTORNEYS AT LAW
1840 DUKE STREET
ALEXANDRIA, VIRGINIA 22314
(703) 413-3000
(703) 413-2220 FACSIMILE
OBLONPAT@OBLON.COM
WWW.OBLON.COM

FACSIMILE

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

I hereby certify that this correspondence is being facsimile transmitted to:

Commissioner for Patents
Alexandria, VA 22313-1450
(703) 872-9306

on Date: June 29, 2004

Signature: Corwin Paul Elmbach

Total number of pages including this page: 6

OSMM&N File No. 220243USOPCT

Dept: CHEMICAL

By: NFO/CL/ltc

Serial No. 10/088,074 previously indicated by the USPTO as 10/070,474

In the matter of the Application of: Stephen ARKINSTALL, et al.


For: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

Due Date: N/A

- ☐ Dep. Acct. Order Form
- ☐ Fax Cover Sheet
- ☐ Supplemental Status Request
- ☐ Filing Receipt dated March 20, 2002
- ☐ Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) (Copy)

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

BEST AVAILABLE COPY



ATTORNEYS AT LAW

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Date: June 29, 2004 Signature: Corwin Paul Umbach
Attorney

To: Examiner: Richard Ross Telephone Number: (703) 308-6155

Group Art Unit: _____

Facsimile No.: (703) 308-6459

From: Corwin P. Umbach, Ph.D. Registration No.: 40,211

Telephone Number: (703) 412 4525

Date: June 29, 2004

RE: U.S. Application Serial Number: 10/088,074 previously indicated by the USPTO as 10/070,474

Filed: March 20, 2002

Attorney Docket Number: 220243USOPCT

TOTAL NUMBER OF PAGES INCLUDING THIS PAGE: 6

COMMENTS

In the event that any fees are due, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge the required fees to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time.

1940 DUKE STREET ■ ALEXANDRIA, VIRGINIA 22314 ■ U.S.A.
TELEPHONE: 703-413-3000 ■ FACSIMILE: 703-413-2220 ■ WWW.OBLON.COM

DOCKET NO. 220243US0 PCT

RECEIVED
CENTRAL FAX CENTER

JUN 29 2004

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :

Stephen ARKINSTALL, et al.

: GROUP ART UNIT:

SERIAL NO: 10/088,074, previously indicated
by the USPTO as 10/070,474 :

FILED: March 20, 2002

: EXAMINER:

FOR: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

OFFICIAL

SUPPLEMENTAL STATUS REQUESTCOMMISSIONER FOR PATENTS
ALEXANDRIA, VA 22313

SIR:

Supplemental to the Second Status Request filed June 22, 2004, attached is a copy of the date-stamped filing receipt dated March 20, 2002, indicating that the above-identified application based on PCT/IB00/01381 has been assigned Application No. 10/070,474. Also attached is a copy of the Notification of Missing Requirements dated May 20, 2002, indicating that the above-identified application based on PCT/IB00/01381 has been assigned Application No. 10/088,074.

The Patent Office is respectfully requested to inform the undersigned of the approximate date on which further action will be taken on this Application.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. OblonCorwin P. Umbach, Ph.D.
Registration No. 40,211

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

OSMM&N File No. 220243USOPCT By NFO/tm/FF Due Date March 28, 2002

Serial No. New U.S. PCT Application based on PCT/IB00/01381

In the matter of the Application of Stephen ARKINSTALL et al.

For PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

The following has been received in the U.S. Patent Office on the date stamped hereon:

- ☐ pgs. Specification ☐ Claims (English Translation) ☐ pgs. Sequence Listing
- ☐ Combined Declaration, Petition & Power of Attorney (☐ pages)
- ☐ Petition to Revive Under 37 C.F.R. 1.137 (b)
- ☒ Notice of Priority;
- ☒ Check for \$ 1,146.00; ☒ Dep. Acct. Order Form
- ☐ Assignment ☐ pages/PTO-1595
- ☐ Drawings ☐ sheets
- ☒ PCT Transmittal Letter
- ☒ Preliminary Amendment
- ☐ PCT/IB/304 ☐ PCT/IB/308
- ☐ Letter Regarding Claim to Small Entity Status
- ☒ International Preliminary Examination Report
- ☒ Information Disclosure Statement; ☒ PTO-1449
- ☒ Cited References (5) ☐ Statement of Relevancy
- ☐ List of Related Cases ☐ Cited Pending Applications(#)
- ☒ International Search Report
- ☐ Request for Consideration of Documents Cited in International Search Report
- ☐ Letter Regarding Translation of Annexes
- ☐ Translation of Annexes to International Preliminary Examination Report
- Amended Sheets ()

SERIAL NO. 10/070474

DATE RECEIVED RCVD PCT/PTO

20 MAR 2002 *per.*

☐ CLAIMING SMALL ENTITY STATUS

at 5/23/02 JUN. 29. 2004 3:52PM

OBLON SPIVAK

NO. 365 Pa. 5012



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/088,074	Stephen Arkinstall	220243US OPCT

INTERNATIONAL APPLICATION NO.
PCT/IB00/01381

LA. FILING DATE	PRIORITY DATE
09/28/2000	09/28/1999

22850
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

CONFIRMATION NO. 7568
371 FORMALITIES LETTER
OC00000008133626

Date Mailed: 05/20/2002

Del/Seg list 7-20-02

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Preliminary Amendments
- Request for Immediate Examination

MAY 23 2002
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT, P.C.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the Inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patent Software, call (703) 306-2600
- For Patent Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/088,074	PCT/IB00/01381	220243US

FORM PCT/DO/EO/905 (371 Formalities Notice)